Core Viewpoint - Xuan Zhu Bio-B (02575) has seen a significant stock price increase, rising over 7% and currently trading at 58.45 HKD, with a transaction volume of 10.77 million HKD, following the inclusion of its innovative drug, Palbociclib, in the national medical insurance drug list [1] Group 1 - The National Healthcare Security Administration announced the adjustment results of the national medical insurance drug list on December 7, 2025, which includes Xuan Zhu Bio's CDK4/6 inhibitor, Palbociclib, providing new insurance reimbursement benefits for patients with advanced breast cancer [1] - The national medical insurance for Palbociclib will officially take effect on January 1, 2026, which is expected to significantly enhance the accessibility of the drug and reduce the financial burden on patients [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 軒竹生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司, 「本公司」） FF301 因本公司是於中華人民共和國註冊的股份有限公司，"法定股本" 之概念不適用於本公司，在上述 「法定/註冊股本」部分所載資料是指本公司的 「已發行股本」。 呈交日期: 2026年1月7日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02575 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 160,701,996 | RMB | | 1 RMB | | 160,701,996 | | 增加 / 減少 (-) | | ...

Core Viewpoint - The inclusion of the innovative drug Pyrotinib in the national medical insurance list is expected to enhance its affordability and accessibility for patients, positively impacting the company's long-term operational development [1] Group 1: Stock Performance - Xuan Bamboo Bio-B (02575) saw an early morning increase of over 6%, and as of the report, it rose by 2.36% to HKD 52.05, with a trading volume of HKD 2.99 million [1] Group 2: Drug Inclusion and Impact - Pyrotinib, a CDK4/6 inhibitor developed by the company, was successfully included in the national medical insurance drug list, effective January 1, 2026, providing new reimbursement benefits for patients with advanced breast cancer [1] - The company stated that the results of the medical insurance negotiations will help improve the drug's affordability and accessibility among patients, facilitating market promotion and increasing sales scale [1] - The company plans to actively cooperate in implementing the medical insurance policy, continue hospital access efforts, expand core markets, and enhance market coverage to improve patient access to the medication [1]

Core Viewpoint - Xuan Bamboo Biotech-B (02575) has seen a stock price increase of 4.33%, currently trading at 53.05 HKD, following the inclusion of its innovative drug, Pyrotinib, in the national medical insurance list, effective January 1, 2026, which will benefit late-stage breast cancer patients [1][5]. Group 1 - The national medical insurance inclusion of Pyrotinib was announced on December 7, 2025, by the National Healthcare Security Administration [1][5]. - The company believes that this insurance negotiation outcome will enhance the affordability and accessibility of its drug, Xuan Yuen Ning, for patients [1][5]. - The company plans to actively support the implementation of the insurance policy, continue hospital access efforts, and expand its core market to improve patient access to medication [1][5].

Core Viewpoint - The stock of Xuan Bamboo Bio-B (02575) has seen a significant increase, with a rise of over 6% in early trading and currently up by 2.36% to HKD 52.05, with a trading volume of HKD 2.99 million. The inclusion of the innovative drug Pyrotinib in the national medical insurance list is expected to enhance its market accessibility and sales growth, positively impacting the company's long-term development [1]. Group 1 - The national medical insurance for Pyrotinib will officially take effect on January 1, 2026 [1]. - Pyrotinib, a CDK4/6 inhibitor developed by the company, has been successfully included in the 2025 national medical insurance drug list, providing new reimbursement benefits for patients with advanced breast cancer [1]. - The company believes that the results of the medical insurance negotiations will help improve the affordability and accessibility of Xuan Yuening among patients, facilitating market promotion and sales growth [1]. Group 2 - The company plans to actively cooperate in implementing the medical insurance policy, continuing to promote hospital access, expanding core markets, and increasing market coverage to enhance patient accessibility to the medication [1].

Core Viewpoint - Xu Yanjun has been appointed as the General Manager of Xuan Bamboo Biotechnology-B (02575), effective from January 5, 2026 [1] Group 1 - The appointment was recommended by the company's nomination committee [1]

Core Viewpoint - Xu Yanjun has been appointed as the General Manager of Xuan Bamboo Bio-B (02575), effective from January 5, 2026, following the recommendation of the company's nomination committee [1] Company Summary - Xu Yanjun's appointment is part of the company's strategic leadership changes aimed at enhancing operational efficiency and driving future growth [1]

Group 1 - The core point of the article is the appointment of Xu Yanjun as the General Manager of Xuan Bamboo Biotechnology-B (02575.HK), effective from January 5, 2026 [1]

董事名單與其角色及職能 Xuanzhu Biopharmaceutical Co., Ltd. 軒竹生物科技股份有限公司 （股份代號：2575） （一家於中華人民共和國註冊成立的股份有限公司） 軒 竹 生 物 科 技 股 份 有 限 公 司 董 事 會（「董事會」）成 員 載 列 如 下： 執行董事 徐艷君女士 （董 事 長 兼 總 經 理） 李嘉逵博士 史澂空博士 獨立非執行董事 劉碩先生 王宇女士 范智超先生 董 事 會 下 設 三 個 委 員 會。下 表 載 列 各 董 事 會 成 員 在 該 等 委 員 會 中 所 擔 任 的 職 位。 | | 委員會 | | 薪酬與 | | | | | --- | --- | --- | --- | --- | --- | --- | | 董 事 | | 審計委員會 | 考核委員會 | | | 提名委員會 | | 徐艷君女士 | | | 成 | 員 | 成 | 員 | | 李嘉逵博士 | | | | | | | | 史澂空博士 | | | | | | | | 李惠英女士 | | | | | | | | 尉麗峰先生 | | | | | | | | 陳燕玲女士 | 成 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 委任總經理 軒 竹 生 物 科 技 股 份 有 限 公 司（「本公司」，連 同 其 附 屬 公 司 統 稱「本集團」）董 事（「董 事」）會（「董事會」）欣 然 宣 佈，經 本 公 司 提 名 委 員 會 推 薦，徐 艷 君 女 士（「徐女士」） 已 獲 委 任 為 本 公 司 總 經 理，自 二 零 二 六 年 一 月 五 日 起 生 效。 徐 女 士 作 為 本 公 司 總 經 理 的 任 期 自 二 零 二 六 年 一 月 五 日 起 計，為 期 三 年。徐 女 士 已 就 擔 任 執 行 董 事 與 本 公 司 訂 立 服 務 合 約，任 期 自 二 零 二 五 年 九 月 五 日 起 計，不 超 過 三 年。徐 女 士 作 為 本 公 司 總 經 理 將 不 會 收 取 額 外 薪 酬。 根 據 香 港 聯 合 交 易 所 有 限 公 司 ...